The effect of antiplatelet therapy in patients with inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 46, Issue 6, 2012, Pages 527-529

  Vinod, Jeevan ^a   Vadada, Deepak ^a   Korelitz, Burton I ^a   Sonpal, Niket ^a   Panagopoulos, Georgia ^a   Baiocco, Peter ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; HUMAN; INTESTINAL BLEEDING; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY;

ASPIRIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 84862286402     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31825003cc     Document Type: Letter

References (10)

1. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007;102:174-186.
2. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1999;353: 1167-1173.
3. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;6:458-466.
4. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: Role of platelets. Gut. 1993;34:247-251.
5. Harries AD, Fitzsimons E, Fifield R. Platelet count: A simple measure of activity in crohn's Disease. Br Med J. 1983;286:1476.
6. Danese S, Fiocchi C. Platelet activation and the CD40/CD40L pathway: Mechanisms and implications for human disease. Crit Rev Immunol. 2005;25:103-121.
7. Danese S, De la Motte C, Sturm A, et al. Platelets trigger a CD40 dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 2003;124:1249-1264.
8. Russell J, Cooper D, Tailor A, et al. Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets. Am J Physiol Gastrointest Liver Physiol. 2003;284: G123-G129.
9. Carty E, Rampton DS, Schneider H, et al. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebocontrolled, double-blind, multi-centre clinical trial in active crohn's disease. Aliment Pharmacol Ther. 2001;15: 1323-1329.
10. Tytgat GN, Van Nueten L, Van De Velde I, et al. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: Two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002;16:87-99.